The Internet and telecom conglomerate SoftBank Group raises $23 billion in the biggest IPO in Japan.

Chanel Holden

2018-12-21 11:39:00 Fri ET

The Internet and telecom conglomerate SoftBank Group raises $23 billion in the biggest IPO in Japan. Going public is part of the major corporate move away from telecommunication toward investing in tech startups through the SoftBank Vision Fund. SoftBank founder and executive director Masayoshi Son runs this fund that receives steady external finance from Saudi Arabia.

The SoftBank mobile move marks the largest-ever IPO in Japan, but its share price plunges more than 14% to 1,404 yen on the first day of trading on the Tokyo stock exchange. This sharp share price decline reflects the fact that many stock market investors tend to overvalue IPOs in Japan as overconfident CEOs try to time the stock market by opportunistically offering private equity stakes to retail investors, fund managers, and other institutional investors.

SoftBank billionaire founder Masayoshi Son is one of the wealthiest investors in the world, and he runs his $100 billion SoftBank Vision Fund as a key global tech investment vehicle. Son maintains good business relations and connections with many unicorn hunters and tech entrepreneurs in Silicon Valley, royal investors in Saudi Arabia, and Internet titans such as Alibaba and Foxconn executive chairmen Jack Ma and Terry Guo in China.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

Response to USPTO fintech patent protection and accreditation

Andy Yeh Alpha

2023-01-09 10:31:00 Monday ET

Response to USPTO fintech patent protection and accreditation

Response to USPTO fintech patent protection As of early-January 2023, the U.S. Patent and Trademark Office (USPTO) has approved our U.S. utility patent

+See More

President Trump criticizes the WTO and proposes indexing capital gains taxes to inflation for U.S. investors.

Charlene Vos

2018-08-29 10:37:00 Wednesday ET

President Trump criticizes the WTO and proposes indexing capital gains taxes to inflation for U.S. investors.

In an exclusive interview with Bloomberg, President Trump criticizes the World Trade Organization (WTO), proposes indexing capital gains taxes to inflation

+See More

Top money managers George Soros and Warren Buffett reveal their current stock and bond positions.

Dan Rochefort

2018-05-10 07:37:00 Thursday ET

Top money managers George Soros and Warren Buffett reveal their current stock and bond positions.

Top money managers George Soros and Warren Buffett reveal their current stock and bond positions in their recent corporate disclosures as of mid-2018. Georg

+See More

A physicist derives a mathematical formula for success.

Chanel Holden

2019-03-07 12:39:00 Thursday ET

A physicist derives a mathematical formula for success.

A physicist derives a mathematical formula that success equates the product of both personal quality and the potential value of a random idea. As a Northeas

+See More

Joseph Stiglitz and Andrew Charlton suggest that free trade helps promote better economic development worldwide.

Monica McNeil

2023-07-21 10:30:00 Friday ET

Joseph Stiglitz and Andrew Charlton suggest that free trade helps promote better economic development worldwide.

Joseph Stiglitz and Andrew Charlton suggest that free trade helps promote better economic development worldwide. Joseph Stiglitz and Andrew Charlton (200

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More